N/A
N=215
Incidence of HANA Conditions in HIV-infected Individuals
HIV · Metabolic Syndrome · Osteopenia · Osteoporosis · Vitamin D Deficiency
Bottom Line
View on ClinicalTrials.gov: NCT03483584 ↗Enrolled (actual)
215
Serious AEs
0.0%
Results posted
Dec 2025
Primary outcome: Primary: Prevalences of HIV-associated Non-AIDS Conditions (HANA) — 69; 15; 30; 4 Participants — p=0.244
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Chinese University of Hong Kong
- Primary completion
- Mar 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Prevalences of HIV-associated Non-AIDS Conditions (HANA) |
69; 15; 30; 4; 79; 9 | 0.244 |
| PRIMARY Incidence Rates of HANA Conditions for At-risk Groups |
14.7; 10.5; 3.3; 9.5; 31.6; 41.9 | — |
Summary
With the availability of effective anti-retroviral therapy, HIV-infected individuals are expected not to die of AIDS and have longer life expectancy. But at the same time, HIV-associated non-AIDS (HANA) conditions are becoming more important in their clinical management. It is currently uncertain whether patients started on different anti-retroviral regimens will have different incidence of HANA conditions.
This study aims to evaluate the incidence of various HANA conditions in a cohort of newly diagnosed HIV-infected individuals in Hong Kong initiating anti-retroviral treatment. The incidence of various HANA conditions will be evaluated for those receiving INSTI versus other non-INSTI-based regimens.
The HANA conditions evaluated will include 1. Hypertension 2. Diabetes and insulin resistance 3. Dyslipidemia 4. Lipodystrophy 5. Metabolic syndrome 6. Osteopenia and osteoporosis 7. Vitamin D deficiency 8. Renal impairment and kidney tubular dysfunction and 9. Liver fibrosis. Patients will be assessed prior to initiation of anti-retroviral therapy, and 48 weeks and 96 weeks after initiation of treatment. The incidence of development of each HANA condition will be determined and compared between those initiated different anti-retroviral regimens.
Eligibility Criteria
Inclusion Criteria
- Confirmed HIV infection by HIV antibody or RNA test
- Age ≥18 years old
- Anti-retroviral treatment naïve
- Agree to initiate anti-retroviral therapy (ART) as determined by in-charge HIV physician
Exclusion Criteria
- Pregnancy
- Unable to give informed consent
Data sourced from ClinicalTrials.gov (NCT03483584). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.